Pharmaceutical

Image

Global Nephrogenic Diabetes Insipidus Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Nephrogenic Diabetes Insipidus Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 313.95 Million
Diagram Market Size (Forecast Year) USD 508.00 Million
Diagram CAGR %

Global Nephrogenic Diabetes Insipidus Market, By Symptoms (Chronic Excessive Thirst (Polydipsia), Excessive Urine Production (Polyuria), Others), Drug Type (Demeclocycline, Ofloxacin, Orlistat), Diagnosis (X-ray Scans, Computed Tomography (CT Scan), Ultrasound, Magnetic Resonance Imaging (MRI)), End Users (Hospitals, Clinics, Pharmaceutical Companies, Others) - Industry Trends and Forecast to 2030.

Nephrogenic Diabetes Insipidus Market Analysis and Size

The rapid rise in the prevalence of diabetes is expected to accelerate the market growth in the forecast period 2023-2030. In addition, the rise in the use of antidiuretic drugs for the treatment of hemophilia and the high incidence of diabetic patients are also predicted to enhance the global nephrogenic diabetes insipidus market growth. Furthermore, the increased government support and the rise in the geriatric population suffering from diabetes insipidus are also projected to drive the market growth rate.

Data Bridge Market Research analyses that the global nephrogenic diabetes insipidus market which was USD 313.95 million in 2022, is expected to reach USD 508.00 million by 2030, and is expected to undergo a CAGR of 6.20% during the forecast period of 2023-2030. This indicates that the market value. "Multivitamin" dominates the product type segment of the global nephrogenic diabetes insipidus market due to increasing awareness about nephrogenic diabetes insipidus. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Nephrogenic Diabetes Insipidus Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Symptoms (Chronic Excessive Thirst (Polydipsia), Excessive Urine Production (Polyuria), Others), Drug Type (Demeclocycline, Ofloxacin, Orlistat), Diagnosis (X-ray Scans, Computed Tomography (CT Scan), Ultrasound, Magnetic Resonance Imaging (MRI)), End Users (Hospitals, Clinics, Pharmaceutical Companies, Others)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa

Market Players Covered

Allergan (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Taj Pharmaceuticals Limited (India), Otsuka Holdings Co. Ltd. (Japan), and Azevan Pharmaceuticals, Inc. (U.S.)

Market Opportunities

  • Rising demand for minimally invasive treatments
  • Development of new formulations and delivery methods
  • Rapid rise in the prevalence of diabetes

Market Definition

Nephrogenic diabetes insipidus (NDI) is a rare kidney disorder characterized by the inability of the kidneys to properly respond to a hormone called antidiuretic hormone (ADH) or vasopressin. ADH helps regulate the balance of water in the body by controlling the reabsorption of water in the kidneys. In individuals with NDI, the kidneys fail to properly respond to ADH, resulting in excessive urine production and frequent urination. This leads to the inability to concentrate urine and causes increased thirst and dehydration.

Global Nephrogenic Diabetes Insipidus Market Dynamics

Drivers

  • Increasing Awareness and Diagnosis

Growing awareness about nephrogenic diabetes insipidus among healthcare professionals and the general population has led to improved diagnosis rates. As a result, more individuals with the condition are being identified and seeking appropriate management and treatment options, thereby driving the demand for products and services related to NDI.

  • Research and Development Initiatives

Ongoing research and development efforts aimed at better understanding the pathophysiology of nephrogenic diabetes insipidus and identifying potential therapeutic targets are driving innovation in the market. This includes the exploration of new drug candidates, gene therapies, and other interventions to improve the management of NDI.

  • Increasing Healthcare Expenditure

Rising healthcare expenditure and investment in healthcare infrastructure, particularly in emerging economies, are contributing to the growth of the global nephrogenic diabetes insipidus market. This allows for improved access to diagnostic tools, medications, and supportive therapies for individuals with NDI.  

Opportunity

  • Advances in Diagnostic Technologies

Technological advancements in diagnostic tools and techniques have facilitated the accurate and early detection of nephrogenic diabetes insipidus. Novel imaging techniques, genetic testing, and biomarker analysis are improving the diagnostic process, enabling prompt and targeted interventions.

Restraint/Challenge

  • Regulatory Challenges

Obtaining regulatory approvals for new nephrogenic diabetes insipidus diagnosis and treatment products involves rigorous testing and evaluation processes. These regulatory hurdles can significantly delay the launch of new drugs, increasing development costs and limiting the market entry of innovative treatments. Adhering to these regulations and obtaining necessary approvals can be time-consuming and costly, hindering market growth.

This global nephrogenic diabetes insipidus market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global nephrogenic diabetes insipidus market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In November 2020, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.

Global Nephrogenic Diabetes Insipidus Market Scope

The global nephrogenic diabetes insipidus market is segmented on the basis of symptoms, drug type, diagnosis, and end users. The growth amongst these segments will help your meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Symptoms

  • Chronic Excessive Thirst (Polydipsia)
  • Excessive Urine Production (Polyuria)
  • Others

Drug Type

  • Demeclocycline
  • Ofloxacin
  • Orlistat

Diagnosis

  • X-ray Scans
  • Computed Tomography (CT Scan)
  • Ultrasound
  • Magnetic Resonance Imaging (MRI)

End Users

  • Hospitals
  • Clinics
  • Pharmaceutical Companies
  • Others

Global Nephrogenic Diabetes Insipidus Market Regional Analysis/Insights

The global nephrogenic diabetes insipidus market is analysed and market size insights and trends are provided by country, symptoms, drug type, diagnosis, and end users as referenced above.

The countries covered in the global nephrogenic diabetes insipidus market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East & Africa.

North America is dominating the global nephrogenic diabetes insipidus market due to the increasing prevalence of nephrogenic diabetes insipidus in that region. The Asia Pacific is the fastest-growing region due to increased awareness of nephrogenic diabetes insipidus.

The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global nephrogenic diabetes insipidus market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global nephrogenic diabetes insipidus market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global nephrogenic diabetes insipidus market. The data is available for historic period 2023-2030.

Competitive Landscape and Global Nephrogenic Diabetes Insipidus Market Share Analysis

The global nephrogenic diabetes insipidus market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global nephrogenic diabetes insipidus market.

Some of the major players operating in the global nephrogenic diabetes insipidus market are:

  • Allergan (Ireland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Taj Pharmaceuticals Limited (India)
  • Otsuka Holdings Co. Ltd. (Japan)
  • Azevan Pharmaceuticals, Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The growth rate of the nephrogenic diabetes insipidus market value was USD 313.95 million in 2022.
The growth rate of the nephrogenic diabetes insipidus market is 6.20% by 2030.
Increasing Awareness and Diagnosis, Research and Development Initiatives & Increasing Healthcare Expenditure are the growth drivers of the nephrogenic diabetes insipidus market.
Symptoms, drug type, diagnosis, and end users are the factors on which the nephrogenic diabetes insipidus market research is based.
Major companies in the nephrogenic diabetes insipidus market are Allergan (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Taj Pharmaceuticals Limited (India), Otsuka Holdings Co. Ltd. (Japan), and Azevan Pharmaceuticals, Inc. (U.S.).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials